Preventive effect of curcumin in cardiac arrhythmia
Phase 3
Completed
- Conditions
- I20.Preinfarction syndrome
- Registration Number
- IRCT2013102315122N1
- Lead Sponsor
- Mashad University of Medical Sciences, Pharmaceutical Research Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Age>18; diagnosis of unstable angina with clinic and para clinic finding.
Exclusion criteria:
Renal and hepatic failure; infectious diseases; NSIADS and immunosuppresion drugs consumption; curcumin sensitivity; pregnancy and feeding; malignancy; chronic inflammatory disease; cardiac arrhythmia; malabsorption syndromes
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Frequency of atrial and ventricular arrhythmia. Timepoint: Between first day to 30th day post unstable angina. Method of measurement: ECG-heart exam.
- Secondary Outcome Measures
Name Time Method Changes in myeloperoxidase serum concentration. Timepoint: in day 0,5,10,15 post unstable angina. Method of measurement: laboratory.;Changes in matrix metaloproteinase serum concentration. Timepoint: in day 0,5,10,15 post unstable angina. Method of measurement: laboratory.;Changes in IL-18 serum concentration. Timepoint: in day 0,5,10,15 post unstable angina. Method of measurement: laboratory.
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms does curcumin utilize to prevent plaque rupturing in unstable angina patients with preinfarction syndrome?
How does curcumin compare to standard anti-arrhythmic drugs in managing atrial and ventricular arrhythmias in phase III trials for preinfarction syndrome?
Which serum biomarkers are evaluated in IRCT2013102315122N1 to assess curcumin's preventive effect on cardiac arrhythmia in preinfarction syndrome patients?
What adverse events are associated with curcumin therapy in phase III trials for preinfarction syndrome, and how are they managed in clinical practice?
Are there combination therapies involving curcumin and antiplatelet agents that enhance plaque stability and reduce arrhythmic risk in preinfarction syndrome patients?